ABT.L -

LSE - LSE Delayed price. Currency in USD
0.00
0.00 (0.00%)
At close: 1:00AM BST
Stock chart is not supported by your current browser
Previous close0.00
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's range0.00 - 0.00
52-week range
Volume0
Avg. volumeN/A
Market capN/A
BetaN/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Tap Cardiovascular Devices Market Boom With These 3 Stocks
    Zacks3 days ago

    Tap Cardiovascular Devices Market Boom With These 3 Stocks

    Consider these three stocks in the rapidly-growing cardiovascular devices market.

  • How Incyte’s Jakafi Performed in Q1 2018
    Market Realist25 days ago

    How Incyte’s Jakafi Performed in Q1 2018

    Incyte’s (INCY) oncology drug Jakafi (ruxolitinib) is approved for the treatment of myelofibrosis and polycythemia vera, two rare types of blood cancer.

  • The Performance of Roche’s Diagnostics Division in Q1 2018
    Market Realistlast month

    The Performance of Roche’s Diagnostics Division in Q1 2018

    Roche’s (RHHBY) Diagnostics division comprises tissue diagnostics, molecular diagnostics, diabetes care, and centralized and point-of-care solutions. Roche’s Diagnostics division grew 5.0% year-over-year to reach ~2.9 billion Swiss francs.

  • How Did Bausch + Lomb Perform in 1Q18?
    Market Realistlast month

    How Did Bausch + Lomb Perform in 1Q18?

    In 1Q18, Valeant Pharmaceuticals’ (VRX) subsidiary, Bausch + Lomb, generated revenues of $1.10 billion compared to $1.13 billion in 1Q17, which reflected an ~3.0% decline on a year-over-year (or YoY) basis. In 1Q18, Bausch + Lomb witnessed 2.0% organic growth compared to 1Q17.

  • A Overview of Merck’s Diabetes Products in 1Q18
    Market Realist2 months ago

    A Overview of Merck’s Diabetes Products in 1Q18

    Merck’s (MRK) diabetes products include blockbuster drugs Januvia (sitagliptin) and Janumet (sitagliptin and metformin hydrochloride). Both drugs are used to control blood sugar levels in patients with diabetes.

  • How Analysts View Allergan after Its 1Q18 Earnings
    Market Realist2 months ago

    How Analysts View Allergan after Its 1Q18 Earnings

    Allergan (AGN) surpassed Wall Street analysts’ estimates for earnings per share (or EPS) and revenues, reporting EPS of $3.74 on revenues of $3.7 billion during 1Q18. Analysts expect Allergan’s top line to fall 3.3% to ~$3.9 billion in 2Q18. Its earnings per share are expected to reach $4.03 in 2Q18. The chart below shows analysts’ recommendations over the last 12 months.

  • Abbott’s Freestyle Libre CGM’s Performance, Growth Prospects
    Market Realist2 months ago

    Abbott’s Freestyle Libre CGM’s Performance, Growth Prospects

    Abbott Laboratories (ABT) received FDA approval for its breakthrough CGM (continuous glucose monitoring) device, Freestyle Libre, in September 2017. For further details, please read Abbott’s Breakthrough CGM Device Freestyle Libre Wins FDA Approval. The company received reimbursement approval for the device from the Centers for Medicare & Medicaid Services in January 2018.

  • Wall Street Recommendations for GlaxoSmithKline after 1Q18
    Market Realist2 months ago

    Wall Street Recommendations for GlaxoSmithKline after 1Q18

    GlaxoSmithKline beat Wall Street Analysts’ estimates for earnings per share (or EPS) and revenues for 1Q18. It reported EPS of 24.60 pence on revenues of 7.22 billion pounds, compared to analysts’ estimated EPS of 24.21 pence at revenues of 7.20 billion pounds.

  • Abbott Laboratories Registered Organic Growth of 7% in 1Q18
    Market Realist2 months ago

    Abbott Laboratories Registered Organic Growth of 7% in 1Q18

    Abbott Laboratories (ABT) is a developer and manufacturer of a broad and diversified line of healthcare products. Its business segments include pharmaceutical products, diagnostic products, nutritional products, and cardiovascular and neuromodulation products.

  • Will BSX’s 1Q18 Results Support Its Upward Trend?
    Market Realist2 months ago

    Will BSX’s 1Q18 Results Support Its Upward Trend?

    Over the last month, BSX stock has registered a rise of ~4.2%. The company came out on top in patent infringement litigation against Edwards Lifesciences (EW), for which a hearing is scheduled in May at the German Court of Appeal. On April 16, Boston Scientific announced its acquisition of Nvision Medical Corporation for a cash payment of $150 million and an additional milestone-based payment over the next four years amounting to $125 million.

  • Johnson & Johnson’s Revenues Continued to Rise in 1Q18
    Market Realist2 months ago

    Johnson & Johnson’s Revenues Continued to Rise in 1Q18

    Johnson & Johnson (JNJ) reported 12.6% growth in its revenues to $20.0 billion during 1Q18 as compared to revenues of $17.8 billion during 1Q17. The company surpassed Wall Street analyst estimates for EPS (earnings per share) and revenues and reported EPS of $2.06 on revenues of $20.0 billion during 1Q18 against estimates for EPS of $2.00 on revenues of $19.4 billion during 1Q17.

  • Top Analyst Reports for Goldman Sachs, Abbott & Altria
    Zacks2 months ago

    Top Analyst Reports for Goldman Sachs, Abbott & Altria

    Top Analyst Reports for Goldman Sachs, Abbott & Altria

  • Aortic Stenosis, And The Race To Catch Edwards Lifesciences' Heart Valves
    Investor's Business Daily2 months ago

    Aortic Stenosis, And The Race To Catch Edwards Lifesciences' Heart Valves

    Edwards Lifesciences, Medtronic, Boston Scientific and Abbott Laboratories are duking it out for a share of the fast-growing heart-valve replacement market.

  • Abbott Shares Topple After Pharma Unit Struggles In First Quarter
    Investor's Business Daily2 months ago

    Abbott Shares Topple After Pharma Unit Struggles In First Quarter

    Shares of Abbott Laboratories dipped early Wednesday — despite its broad first-quarter beat — on pharmaceutical sales that lagged Wall Street's expectations by nearly 4%.

  • Abbott’s Stock Price Momentum Continues: What’s Ahead?
    Market Realist2 months ago

    Abbott’s Stock Price Momentum Continues: What’s Ahead?

    On April 5, 2018, Abbott Laboratories (ABT) ended the trading day at $59.86 per share. The stock registered a rise of ~0.67% in its stock price compared to its previous day’s close. For more details, read Abbott Laboratories Traded at a 52-Week High after Posting Strong 4Q17 Results.

  • Better Buy: AbbVie Inc. vs. Johnson & Johnson
    Motley Fool3 months ago

    Better Buy: AbbVie Inc. vs. Johnson & Johnson

    Which big pharma stock wins when it comes to growth, income, and value?

  • Market Realist7 months ago

    What Abbott’s Recent Stock Performance Tells Us

    On November 20, 2017, Abbott Laboratories (ABT) stock closed at $55.3. The company reported its 52-week high of $56.7 on October 23, 2017.

  • Market Realist7 months ago

    Decoding Abbott Laboratories’ Latest Fiscal 2017 Guidance

    During its 3Q17 earnings release on October 18, 2017, Abbott Laboratories (ABT) provided an updated guidance for fiscal 2017 and 4Q17.

  • Market Realist8 months ago

    What to Expect from Abbott Laboratories’ 3Q17 Earnings

    The 3Q17 EPS estimate for Abbott Laboratories is $0.65. The company has provided an EPS guidance range of $0.64–$0.66 for 3Q17.

  • Market Realist8 months ago

    Inside Abbott’s 3Q17 Revenue Expectations: Hit or Miss?

    Analysts expect Abbott Laboratories to report 3Q17 revenues of ~$6.7 billion, representing a YoY (year-over-year) growth of ~26.7%.

  • Market Realist9 months ago

    Can Abbott’s Latest Approval Accelerate Its Established Pharmaceuticals Business?

    On August 30, ABT announced the regulatory approval for its dydrogesterone oral medication in Russia and the Netherlands for invitro fertilization treatment.

  • Market Realist9 months ago

    Reading Abbott’s FDA Approval for MR-Conditional Labeling for Its Ellipse ICD

    On September 22, 2017, Abbott Laboratories (ABT) announced the FDA approval of the MR-conditional labeling for its Ellipse ICD.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes